ABSTRACT
Background and Aims COVID-19 patients may have asymptomatic hyperlipasemia without abdominal imaging findings or abdominal pain. In addition, primary and secondary pancreatitis have been described in COVID-19 patients. There is limited information on how the groups compare in outcomes. The aim is to compare outcomes among these groups.
Methods This is a retrospective study from 12 hospitals within one healthcare system examining outcomes between hospitalized COVID-19 patients with a lipase <3x upper limit of normal (ULN), asymptomatic hyperlipasemia (>3x ULN), secondary pancreatitis (typical respiratory COVID-19 symptoms and found to have pancreatitis), and primary pancreatitis (presenting with pancreatitis).
Results Of 11,883 patients admitted with COVID-19, 1,560 patients were included: 1,155 COVID-19 patients with a normal serum lipase (control group), 270 with an elevated lipase <3x ULN, 46 patients with asymptomatic hyperlipasemia with a lipase 3xULN, 57 patients with secondary pancreatitis, and 32 patients with primary pancreatitis. On adjusted multivariate analysis, the elevated lipase <3x ULN and asymptomatic hyperlipasemia groups had worse outcomes. The mortality was OR1.6 (95% CI 1.2-2.2) and 1.1 (95% CI 0.5-2.3), respectively. The need for mechanical ventilation was OR 2.8 (95% CI 1.2-2.1) and 2.8 (95% CI 1.5-5.2), respectively. Longer length of stay was OR 1.5 (95%CI 1.1-2.0) and 3.16 (95%CI 1.5-6.5), respectively.
Conclusion COVID-19 patients with an elevated lipase< 3x ULN and asymptomatic hyperlipasemia have generally worse outcomes than those with pancreatitis. This could be attributed to extrapancreatic causes (liver failure, renal failure, enteritis, etc), which may signify a more severe course of clinical disease.
Competing Interest Statement
PCB: Consultant for Olympus America, Apollo Medical, FujiFilm, and Boston Scientific JB: Consultant and speaker for Abbvie Inc. AJT: Consultant for Olympus America and Pentax Medical Research Support form Ninepoint Medical
Funding Statement
This project was unfunded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board approval (IRB #20-0200, Registry of patients who are presenting under the suspicion of COVID-19) was obtained for this study by the Northwell Health Feinstein Institute for Medical Research, Office of the Human Research Protection Program (Hallie Kassan, MD; Director)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
GRANT SUPPORT: None
CONFLICT OF INTEREST AND SOURCE OF FUNDING DISCLOSURE:
PCB: Consultant for Olympus America, Apollo Medical, FujiFilm, and Boston Scientific
JB: Consultant and speaker for Abbvie Inc.
AJT: Consultant for Olympus America and Pentax Medical Research Support form Ninepoint Medical
Conception and design (SI, PB, AJT)
Analysis and interpretation of the data (SI, PCB, DW, YL, JB, SKP, AJT)
Drafting of the article (SI, PCB, DW, YL, JB, SKP, AJT)
Critical revision of the article for important intellectual content (SI, PCB, DW, YL, JB, SKP, AJT)
Final approval of the article (SI, PCB, DW, YL, JB, SKP, AJT)
FUNDING: None
Data Availability
Data is available upon request
